Safety/efficacy of MK-8669 (ridaforolimus) plus MK-2206 (AKT inhibitor) in patients with advanced breast cancer with low RAS signature and PTEN deficient prostate cancer

被引：0
|
作者：
Gupta, Shilpa
Munster, Pamela N.
Hollebecque, Antoine
Argues, Guillem
Dajanl, Olav
Chang, Jonathan D.
Swift, Ann M.
Tosolini, Alessandra
Piha-Paul, Sarina Anne
机构：
[1] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA
[2] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
[3] Gustave Roussy, Drug Dev Dept DITEP, Villejuif, France
[4] Vall dHebron Univ Hosp, Barcelona, Spain
[5] Oslo Univ Hosp, Dept Oncol, Oslo, Norway
[6] Merck & Co Inc, Whitehouse Stn, NJ USA
[7] Merck & Co Inc, N Wales, PA USA
[8] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase Program 1, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.2509
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2509
引用
收藏
页数：1
相关论文
共 49 条
  • [1] SAFETY AND EFFICACY OF MK-8669 (RIDAFOROLIMUS) + MK-2206 (AKT INHIBITOR) IN PATIENTS WITH ADVANCED BREAST CANCER WITH PI3K PATHWAY DEPENDENCE
    Gupta, S.
    Munster, P.
    Hollebecque, A.
    Argiles, G.
    Guren, T.
    Cheng, J.
    Wang, R.
    Swift, A.
    Tosolini, A.
    Piha-Paul, S.
    ANNALS OF ONCOLOGY, 2014, 25 : 25 - 25
  • [2] Biomarkers of response to Akt inhibitor MK-2206 in breast cancer
    Sangai, Takafumi
    Akcakanat, Argun
    Chen, Huiqin
    Tarco, Emily
    Wu, Yun
    Do, Kim-Anh
    Miller, Todd W.
    Arteaga, Carlos L.
    Mills, Gordon B.
    Gonzalez-Angulo, Ana M.
    Meric-Bernstam, Funda
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [3] Biomarkers of Response to Akt Inhibitor MK-2206 in Breast Cancer
    Sangai, Takafumi
    Akcakanat, Argun
    Chen, Huiqin
    Tarco, Emily
    Wu, Yun
    Do, Kim-Anh
    Miller, Todd W.
    Arteaga, Carlos L.
    Mills, Gordon B.
    Gonzalez-Angulo, Ana Maria
    Meric-Bernstam, Funda
    CLINICAL CANCER RESEARCH, 2012, 18 (20) : 5816 - 5828
  • [4] Presurgical evaluation of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer.
    Kalinsky, Kevin
    Sparano, Joseph A.
    Andreopoulou, Eleni
    Taback, Bret
    Wlechmann, Lisa Silvia
    Feldman, Sheldon M.
    Ananthakrishnan, Preya
    Hibshoosh, Hanina
    Manavaian, John
    Crew, Katherine D.
    Maurer, Matthew A.
    Hershman, Dawn L.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [5] Presurgical evaluation of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer.
    Kalinsky, K.
    Sparano, J. A.
    Kim, M.
    Crew, K. D.
    Maurer, M. A.
    Taback, B.
    Feldman, S. M.
    Hibshoosh, H.
    Wiechmann, L.
    Adelson, K. B.
    Hershman, D. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [6] Akt inhibitor MK-2206 reduces pancreatic cancer cell viability and increases the efficacy of gemcitabine
    Wang, Zhanshan
    Luo, Guangtao
    Qiu, Zhengjun
    ONCOLOGY LETTERS, 2020, 19 (03) : 1999 - 2004
  • [7] MK-2206, an Akt inhibitor, enhances carboplatinum/paclitaxel efficacy in gastric cancer cell lines
    Almhanna, Khaldoun
    Cubitt, Christopher L.
    Zhang, Shumin
    Kazim, Sabiha
    Husain, Kazim
    Sullivan, Daniel
    Sebti, Said
    Malafa, Mokenge
    CANCER BIOLOGY & THERAPY, 2013, 14 (10) : 932 - 936
  • [8] Results of an abbreviated phase-II study with the Akt Inhibitor MK-2206 in Patients with Advanced Biliary Cancer
    Ahn, Daniel H.
    Li, Junan
    Wei, Lai
    Doyle, Austin
    Marshall, John L.
    Schaaf, Larry J.
    Phelps, Mitch A.
    Villalona-Calero, Miguel A.
    Bekaii-Saab, Tanios
    SCIENTIFIC REPORTS, 2015, 5
  • [9] Results of an abbreviated phase-II study with the Akt Inhibitor MK-2206 in Patients with Advanced Biliary Cancer
    Daniel H. Ahn
    Junan Li
    Lai Wei
    Austin Doyle
    John L. Marshall
    Larry J. Schaaf
    Mitch A. Phelps
    Miguel A. Villalona-Calero
    Tanios Bekaii-Saab
    Scientific Reports, 5
  • [10] Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation
    Yan Xing
    Nancy U. Lin
    Matthew A. Maurer
    Huiqin Chen
    Armeen Mahvash
    Aysegul Sahin
    Argun Akcakanat
    Yisheng Li
    Vandana Abramson
    Jennifer Litton
    Mariana Chavez-MacGregor
    Vicente Valero
    Sarina A. Piha-Paul
    David Hong
    Kim-Anh Do
    Emily Tarco
    Dianna Riall
    Agda Karina Eterovic
    Gerburg M. Wulf
    Lewis C. Cantley
    Gordon B. Mills
    L. Austin Doyle
    Eric Winer
    Gabriel N. Hortobagyi
    Ana Maria Gonzalez-Angulo
    Funda Meric-Bernstam
    Breast Cancer Research, 21
12345